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ABSTRACT
Liposarcoma (LPS) is the most common type of soft tissue sarcoma accounting 
for 20% of all adult sarcomas. Due to absence of clinically effective treatment options 
in inoperable situations and resistance to chemotherapeutics, a critical need exists 
to identify novel therapeutic targets. We analyzed LPS genomic landscape using 
SNP arrays, whole exome sequencing and targeted exome sequencing to uncover 
the genomic information for development of specific anti-cancer targets. SNP array 
analysis indicated known amplified genes (MDM2, CDK4, HMGA2) and important 
novel genes (UAP1, MIR557, LAMA4, CPM, IGF2, ERBB3, IGF1R). Carboxypeptidase 
M (CPM), recurrently amplified gene in well-differentiated/de-differentiated LPS was 
noted as a putative oncogene involved in the EGFR pathway. Notable deletions were 
found at chromosome 1p (RUNX3, ARID1A), chromosome 11q (ATM, CHEK1) and 
chromosome 13q14.2 (MIR15A, MIR16-1). Significantly and recurrently mutated 
genes (false discovery rate < 0.05) included PLEC (27%), MXRA5 (21%), FAT3 
(24%), NF1 (20%), MDC1 (10%), TP53 (7%) and CHEK2 (6%). Further, in vitro 
and in vivo functional studies provided evidence for the tumor suppressor role 
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INTRODUCTION
Liposarcoma (LPS) is a rare cancer with a high 
recurrence rate and low response to existing therapies 
[1]. To date, surgery is the only therapeutic strategy for 
treating aggressive LPS, but most of these tumors recur 
and metastasize associated with a high mortality [2]. LPSs 
are classified according to World Health Organization into 
five types [3], 1) Atypical lipomatous tumors (ALT)/Well-
differentiated LPS (WDLPS); 2) De-differentiated LPS 
(DDLPS); 3) Myxoid LPS (MLPS); 4) Pleomorphic LPS 
(PLPS) and 5) Mixed-type LPS. Among these, WDLPS 
and DDLPS are the most frequent types occurring in 40-
50% of all LPS cases and are characterized by the presence 
of supernumerary ring and/or giant marker chromosomes 
[4]. The other common type, MLPS is characterized by 
the recurrent translocation t(12;16)(q13;p11) that results in 
the FUS-CHOP gene fusion present in over 95% of MLPS 
cases [5]. PLPS is a rare variety with limited molecular 
studies. 
Studies characterizing the genetic alterations in 
LPS have focused on analysis of copy number, mRNA 
expression and DNA sequences of limited number 
of candidate genes. Several groups have discovered 
amplification on chromosome 12q in the majority of 
WDLPS and DDLPS patients including HMGA2, CDK4 
and MDM2 oncogenes [6, 7]. A DNA sequencing study 
identified frequent mutations of TP53 and RB1 in PLPS, 
NF1 in PLPS and PIK3CA and KIT in MLPS patients [7]. 
In addition, next generation sequencing approach revealed 
structural complexities in primary and locally recurrent 
DDLPS samples and discovered recurrent mutations of 
HDAC1, MAPKAP1, PTPN9 and DAZAP2 [8]. Despite 
these previous reported genetic studies in LPS, no single 
drug against any genomic target in this disease is yet 
approved; necessitating the drive to find and validate 
clinically relevant therapeutic targets in this disease. Since 
LPS remains relatively underserved by large sequencing 
groups, we pursued to define the genomic landscape using 
SNP Chip and next generation sequencing to identify the 
full spectrum of driver mutant genes and altered pathways 
in different types of LPS. 
Here, we report a variety of genomic aberrations 
including mutations, and copy number changes in 
different types of LPS using SNP-CHIP array, whole 
exome sequencing (WES), and targeted exome sequencing 
(TES). The present study defines the genetic landscape 
of LPS highlighting a potentially druggable alteration 
of Carboxypeptidase M (CPM) gene. Integrative exome 
sequencing, SNP analysis and biological studies revealed 
tumor suppressor role of Neurofibromin 1 (NF1) in LPS. 
Pathway analysis of frequently altered genes indicated 
involvement of various important pathways such as 
signalling through MAPK and Erb in LPS leading to 
identification of genes that can be potentially targeted 
using currently available drugs. Comprehensive genomic 
characterization efforts to catalog altered genes and 
pathways will improve our understanding of the molecular 
genetics of LPS for better management of the disease. 
RESULTS
We analyzed LPS samples of different types through 
a combination of next generation sequencing approach 
including SNP arrays of 86 patients and 13 cell lines, WES 
of 12 patients, and TES of 86 patients and 13 cell lines 
(Supplementary Table S1). 
Copy number analysis of LPS samples
SNP array analysis of 86 LPS patient samples 
revealed chromosomal regions most frequently 
aberrant as shown in the heat map (Figure 1A) grouped 
according to subtypes. Among the recurrent copy number 
amplifications, we found previously reported classical 
amplicon at chromosome 12q13-15 involving important 
well-known oncogenes such as [HMGA2 [9], CDK4 [7], 
MDM2 [7] and miR-26-a2 [10] in WDLPS and DDLPS 
patient samples. In addition, GISTIC analysis indicated 
statistically significant, frequently observed broad and 
focal amplifications at chromosomes 1q, 6q, 8q, 11p, 
12q, 14q and 15q (Figure 1B). Interestingly, we observed 
important but previously not reported genes: UAP1, 
MIR557, LAMA4, GRM1, IGF2, CPM, IGF1R, ERBB3, 
STAT6, and MIR492 in the amplified regions. Significant 
deletions were observed at chromosomes 1p, 3p, 6p, 11q, 
13q, 15q and 17p (Figure 1B) indicating important novel 
aberrated genes: RUNX3, CDKN2C, ARIDIA, BCAR3, 
CDKN1C, CCND1, MIR15-A, MIR16-1, TP53BP1. All the 
significantly altered regions and genes within the regions 
identified in LPS samples using GISTIC analysis are listed 
in Supplementary Table S2. 
for Neurofibromin 1 (NF1) gene in different subtypes of LPS. Pathway analysis of 
recurrent mutations demonstrated signaling through MAPK, JAK-STAT, Wnt, ErbB, 
axon guidance, apoptosis, DNA damage repair and cell cycle pathways were involved 
in liposarcomagenesis. Interestingly, we also found mutational and copy number 
heterogeneity within a primary LPS tumor signifying the importance of multi-region 
sequencing for cancer-genome guided therapy. In summary, these findings provide 
insight into the genomic complexity of LPS and highlight potential druggable pathways 
for targeted therapeutic approach.
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Of note, SNP array of 13 LPS cell lines (included 
all the histological types of LPS) displayed comparatively 
more copy number aberrations than the patient samples 
as seen in the heat map (Figure 1C). Heat map showed 
that unlike the other cell lines, SW872 did not have 
the common copy number alterations (CNAs) (gain at 
chromosomes 1, 2, 12 and loss at chromosomes 11, and 
13). MLS402 cells had fewer CNAs compared to other 
LPS cell lines, thus more resembling the profiling pattern 
of the LPS patient samples. GISTIC analysis indicated 
important and significantly recurrent broad amplifications 
and deletions in LPS cell lines including amplification 
at chromosomes 1p (JUN, MIR214, MIR1992A), 
5p15.33 (TERT), 10p13, 12q13-15, and 20q12 (Figure 
1D). Important and novel deletions were identified 
at chromosomes 3p14.2 (FHIT), 8p23.3 (MIR596, 
ARHGEF10, FBXO25), and 16q12.2 (CYLD, RBL2, 
SALL1) (Figure 1D). List of regions and genes observed 
in GISTIC analysis is provided in Supplementary Table 
S3. The focal amplifications and deletions noted in the 
cell lines provide a suitable platform for biological studies 
(Table 1).
Frequent amplification of CPM gene in WDLPS/
DDLPS
In addition to the above mentioned recurrent copy 
number aberrations, we detected gain/amplification of 
the CPM gene at chromosome 12q15 in 78% (39/50) of 
WDLPS/DDLPS patient samples (Figure 2A) which was 
validated using genomic quantitative PCR (Supplementary 
Fig. S1A). CPM protein levels were significantly higher 
in WDLPS/DDLPS samples as shown by positive 
immunohistochemical staining, whereas the protein was 
not detectable in benign lipoma and normal fat tissue 
(Figure 2B and Supplementary Fig. S1B). In addition, 
CPM was amplified in T1000, T778, LPS141, FU-
DDLS-1, SA-4, LPS1, LPS2 and LPS3 cells. Western 
blotting revealed high CPM expression in all CPM 
amplified cell lines compared with the non-amplified 
SW872 cells (Supplementary Fig. S1C). Flow cytometry 
showed CPM surface expression on these CPM amplified 
cell lines suggesting this enzyme may be an attractive 
therapeutic target (Supplementary Fig. S1D). 
Functional role of CPM was characterized in 
LPS141 and FU-DDLS-1 cells (CPM amplification) 
compared to SW872 cells (without CPM amplification). 
CPM knockdown using siRNA1 and siRNA2 versus 
Table 1: Important and selected copy number alterations in LPS cell lines relevant to transformation
Cell Line(s) Alteration Chromosome Selected Gene(s)
SW872 HD 10q23.31 PTEN
T1000, T778 AMP 4p15.2 PPARGC1A
LPS141 HD 9p23 PTPRD
MLS402 HD 3p14.2 FHIT
MLS402 UPD 13q14.2-14.3 RB1, SETDB2, RCBTB1, DLEU2, MIR15-A, MIR16-1,
T778, FU-DDLS-1, LP6, 
MLS402 AMP 5p15.33 TERT
FU-DDLS-1, MLS402, 
LPS141, AMP 5p15.2 CTNND2
MLS402 AMP 11q22 YAP1, BIRC2, BIRC3
MLS402 AMP 14q22.2 CDKN3
LiSa-2 AMP 19q13 PAK4, AKT2
LiSa-2 HD 13q RB1, SETDB2, RCBTB1, DLEU2, MIR15-A, MIR16-1,
LiSa-2 HD 3p24 RBMS3
GOT-3 HD 9q33.1 DEC1
LPS141, GOT-3 HD 16q23 WWOX
GOT-3 AMP Xp22.31 PNPLA4
LPS1, LPS2, LPS3, SA4, HD 9p21.3 CDKN2A, CDKN2B
SA4 HD 10p14 GATA3
SA4 HD 10p11.21 PARD3
SA4 HD 15q15.3 TP53BP1
LiSa-2 HD 16q12.2 RBL2, CYLD, SALL1, SIAH
FU-DDLS-1, LPS1, LPS2, 
LPS3, LP6 AMP 1p32.1 JUN
HD: homozygous deletion; AMP: amplification; UPD: uniparental disomy
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scramble siRNA inhibited cell proliferation of LPS141 
and FU-DDLS-1, but not in SW872 (Supplementary 
Figs. S2A and S2B). To analyze long-term effects of 
CPM knockdown, lentivirus containing CPM shRNA was 
stably infected into these cells (Figure 2C) resulting in 
significant reduction in cell growth (Figure 2D), colony 
formation, migration and invasion (Supplementary Figs. 
S2C-E) in LPS141 and FU-DDLS-1 (not in SW872). 
Also LPS141 and FU-DDLS-1 CPM shRNA expressing 
cells had significantly increased apoptosis compared to 
SW872 cells (Figure 2E and Supplementary Fig. S2F). In 
addition, a significant decreased in vivo tumor growth of 
CPM knockdown LPS141 cells was observed compared 
to wild type LPS141 cells in NSG mice (Figure 2F). One 
important function of CPM is enzymatic cleavage of the 
C-terminal arginine of epidermal growth factor (EGF) in 
tissues suggesting CPM may be involved in activation 
of EGF/EGFR signalling [11]. We found that CPM 
knockdown decreased expression levels of phosphorylated 
EGFR, Akt, and ERK in LPS141 and FU-DDLS-1 cells 
but not in SW872 cells (Figure 2G). Levels of p21 protein 
increased upon CPM knockdown in LPS141 and FU-
DDLS-1 cells compared to non-target shRNA (Nt-shRNA) 
control cells. Taken together, high levels of CPM in LPS 
cells stimulate the transformed features of LPS.
Discovery of somatic mutations through WES
WES was performed on 12 LPS human samples 
of different types and their matched normal tissues as a 
Discovery Set. Average coverage was 185-fold and 80% 
of bases were covered efficiently for variant calls (≥20X 
coverage) (Supplementary Table S4, Supplementary Fig. 
S3). A total 377 potential somatic changes were identified 
and Sanger sequencing validated 91% of events (Figure 
3A, Supplementary Table S5). Clinical characteristics of 
the patients along with some of the important mutated 
genes (BRCA1, MXRA5, NF1, CDK11A and CDK1) and 
Figure 1: Copy number alterations (CNAs) in LPS samples and cell lines. Heat map of the CNAs of A. 86 LPS patient samples 
and C. 13 LPS cell lines grouped by various histotypes. Red and blue represents copy gain and loss, respectively in units of log2 (cancer/
normal). GISTIC analysis demonstrating significant genomic amplifications (red) and deletions (blue) in the B. LPS patient samples and D. 
LPS cell lines genome with chromosome number along the y axis and statistical significance of the aberrations displayed as FDR q values 
along the x axis. Chromosomal peaks and the cancer-related genes within those peaks are shown. 
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copy number changes (CPM, JUN, PIK3CA, CDKN2A, 
CDK4, HMGA2, MDM2, NF1) are shown in Figure 3B. 
Cancers often have variable mutational spectra pointing 
to particular mutagenic stimuli [12]. Only mutational 
signature 1 (Figure 3C) was observed in the Discovery 
cohort in which majority of changes were C > T transitions 
and C > A transversions representing involvement of an 
endogenous mutational process due to deamination of 
5-methyl-cytosine [12].
Landscape of LPS mutations
Prevalence Set of an additional 86 LPS patient 
samples (Supplementary Table S1) and 13 cell lines were 
examined by TES. 248 genes (somatically mutated in the 
Discovery Set and well-known cancer-related genes) were 
evaluated (Supplementary Table S5). Average coverage 
was 121-fold, and 79% of bases were covered efficiently 
for variant calls (≥ 20X coverage) (Supplementary Table 
S6). After removing mapping errors and known SNPs, 
a total of 995 non-synonymous mutations including 
insertions/deletions were identified (Supplementary 
Fig. S4A, Supplementary Table S7) in patient samples. 
Figure 2: Role of CPM in liposarcomagenesis. A. Recurrent genomic copy number gains (red lines) at chromosome 12q13-15 
demonstrated as integral chromosome view (top) using CNAG SNP analysis of WDLPS and DDLPS patient samples. Red lines on top 
shows the recurrent amplified regions along with the important genes. B. Immunohistochemical staining (IHS) of CPM protein in LPS 
tissue microarray. H&E staining (top row) shows the morphology and CPM IHS (bottom row) of tissue of normal fat, benign lipoma, 
MLPS, WDLPS and DDLPS (x100). C. Stable silencing of CPM gene in LPS cell lines using shRNA confirmed by Western blot (GAPDH, 
internal control). D. Effect of CPM knockdown on cellular proliferation using MTT assay in LPS141, FU-DDLS-1 and SW872 cells 
compared to Non-target (Nt)-shRNA. E. Effect of CPM shRNA on apoptosis of LPS cells using Annexin-V-FITC and Propidium iodide 
staining followed by flow cytometry. F. Effect of CPM shRNA3 on LPS141 xenograft growth in vivo in NSG mice. Top panel shows 
dissected tumors from the control (Nt-shRNA) and CPM-shRNA3 tumor containing mice. No growth (NG). Bottom panel: Tumor weight 
was significantly lower in CPM knockdown tumors compared to Nt-shRNA tumors. G. CPM-shRNA3 and Nt-shRNA expressing LPS141, 
FU-DDLS-1, and SW872 cells were analyzed using a variety of antibodies to detect changes in EGFR signaling. (Actin, internal loading 
control). Values of Panels D.-F. are presented as the mean ± SE (n = 3). * P < 0.05 compared with the control group. [Note: Value of S.E. 
are too small to be visible in Panel D]
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Figure 3: Genetic heterogeneity of LPS using WES and TES. A. Total number of alterations observed by WES in patient samples 
in Discovery cohort (Top Panel). Patient characteristics are shown in second panel. B. Mutational profiling using WES and copy number 
profiling (SNP array) in Discovery cohort. C. Mutational signature found in LPS Discovery Cohort. X axis demonstrate mutational type; 
Y axis show relative coefficient of each substitution to the signature. Six types of substitutions are displayed in different color probability 
bars. D. Topography of validated genomic alterations in LPS Prevalence cohort and 13 LPS cell lines. Each column represents an individual 
patient grouped according to histotype and cell lines; and each row indicates a gene. Number of mutations detected for each gene across the 
cohort represented to the right of the heat map. Significantly altered genes are highlighted in bold and red color.
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Figure 4: Functional analysis of altered NF1 gene. A. Western blotting analysis of LPS141 and MLS402 cells stably infected 
with NF1 shRNA1, NF1 shRNA2 and Nt-shRNA (control) after 72 h of transduction. B. Proliferation assay at 24, 48, and 72 hours using 
MTT. C. Soft agar clonogenic growth of NF1 knockdown cells compared to Nt-shRNA. D. In vivo xenograft assay of NF1-knockdown 
of LPS141 cells compared to Nt-shRNA infected cells (NG, no growth). Bar graph (right) indicate tumor weight of NF1 knockdown 
xenografts compared to Nt-shRNA. All assays are representative of three independent experiments (mean ± S.E.; *P < 0.05). Unpaired 2 
tailed Student’s t test was used to calculate all P values. [Note: Value of S.E. are too small to be visible in the panel B]
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Mutational Significance in Cancer (MuSiC) tool was used 
to identify significantly altered genes; important mutated 
genes included MXRA5, PLEC, NF1, FAT3, TP53, MDC1, 
CHEK2 and MDC1 which were significantly enriched for 
mutations (q value < 0.05) (Supplementary Table S8). 
Recurrent mutations in previously unidentified genes 
were found in LPS samples associated with cell adhesion 
and cytoskeleton organization [51 of 86 (60%) patients] 
including mutant PLEC, FAT3, MXRA5, APC, LLGL1, and 
PTPRD (Figure 3D, Supplementary Fig. S4B). Altered 
genes in DNA replication, DNA damage checkpoint and 
repair pathways were detected in 65% of cases. Genetic 
alterations in the cell cycle pathway were found in G1/S 
transition control due to amplifications of CDK4 and 
MDM2 in 70% of samples, including those important 
mutations or deletions of RB1, CDKN2A, CHEK2, TP53 
and ATM genes. Mutations of genes critical for various 
tyrosine kinase pathways were also identified in 36% of 
samples (Figure 3D).
Interestingly, a class of genes involved in axon 
guidance pathway (ROBO1, SEMA3G and SEMA3A) were 
mutated in patient samples (Figure 3D). ROBO1 was also 
mutated in 4 LPS cell lines [LPS1, LPS3, LP6 and T1000] 
(Supplementary Table S7). Genomic aberrations in these 
genes in LPS have not been reported. Using TES and copy 
number analysis, we identified NF1 mutations (including 
5 frameshift insertions) in 17 patient samples and loss of 
heterozygosity in 5 LPS patient samples (Supplementary 
Figs. S5A-B). NF1 silencing using shRNA (Figure 4A) 
significantly increased cell proliferation (Figure 4B) and 
colony formation (Figure 4C) in LPS141 and MLS402 
cells. In vivo stable NF1 knockdown resulted in increased 
human LPS growth in a NSG xenograft model (Figure 
4D) suggesting a tumor suppressor role of this gene that is 
frequently aberrant in different types of LPS. 
Screening of LPS cell lines with targeted capture 
baits revealed various important gene mutations (TP53, 
ROBO1, FAT3, CDKN2A, MXRA5, PLEC and BRAF) 
(Supplementary Table S7). SA-4 and SW872 had the 
most common BRAF oncogenic mutation (V600E) 
and also two LPS patient samples had BRAF missense 
mutations (Figure 5A and Supplementary Fig. S5C). In 
further studies, SA4 (BRAF V600E), SW872 (BRAF 
V600E) and LP6 (BRAF Wild-type) cells were cultured 
in the presence of a small molecule BRAF V600 mutant 
inhibitor vemurafenib. Only the BRAF mutant cells 
were sensitive to the growth inhibitory effects of the 
vemurafenib compared to the BRAF wild-type cells as 
measured by cell growth in liquid culture (Figure 5B) and 
clonogenic assay (Figures 5C and 5D).
Figure 5: Functional analysis of altered BRAF gene in LPS cell lines. A. Sanger sequencing analysis of oncogenic BRAF 
(V600E) mutation in the LPS cell lines. Arrow indicates the position of mutation which was only present in SA4 and SW872 cells. B. Cell 
viability by MTT assay; C. anchorage-dependent colony assay of SW872, SA4 and LP6 cells treated with either BRAF mutant inhibitor 
vemurafenib or DMSO. D. Absorbance readings of stained colonies. All assays are representative of three independent experiments (mean 
± S.E.; *P < 0.05). Unpaired 2 tailed Student’s t test was used to calculate all P values.
Oncotarget42437www.impactjournals.com/oncotarget
Pathways in liposarcoma
We performed pathway analyses of recurrently 
mutated genes of LPS samples using PathScan algorithm 
for improved and better understanding of potential 
mechanism of liposarcomagenesis (Supplementary Table 
S9). Pathways potentially involved in the disease include 
signaling through MAPK (P = 1.78 X 10‐14), ErbB (P = 
3.1 X10‐11), JAK-STAT (P = 2.5 X 10‐11), and Wnt (P = 
4.1 X 10‐7) as well as apoptosis (P = 3.6 X10‐13), cell cycle 
(P = 0.0004), DNA replication (P = 0.009) and repair (P = 
0.0003), and axon guidance pathway (P = 0.0002).
Somatic intra-tumoral genetic heterogeneity 
analysis
WES and SNP arrays were performed on three 
different regions (T1, T2, and T3) of the patient’s large 
DDLPS tumor along with germline normal control (N). 
Average coverage of WES data was 155-fold and 83% of 
bases were covered for variant calling ( > 20X coverage). 
SNP array identified frequent shared copy number events 
in all three tumor regions including FGFR1 amplification 
at chromosome 8p11.23 and classical CDK4, HMGA2 
and MDM2 amplification at chromosome 12q13-15 
region and deletion of TP53BP1 at chromosome 15q15 
(Figure 6A). However, region T2 exclusively contained 
Figure 6: Landscape of intra-tumor heterogeneity. A. CNAG copy number plot of three different tumor regions (T1, T2 and T3) of 
the same LPS tumor. Copy number gain and loss of several genes are highlighted. Red arrow indicates the hemizygous loss of chromosome 
13q only in region T2. B. Distribution of somatic mutations found by WES. Each row indicates the tumor region, and each column represents 
validated somatic mutations. Mutations are grouped as “common” to all 3 tumors, “shared” are common mutations shared by only 2 of the 
3 regions, and “private” found only in single tumor region. C. Venn diagram shows distribution of mutations across all three tumor regions. 
D. Phylogenetic relationships of three different tumor regions. Potential driver alterations are indicated in the branch (arrows).
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hemizygous loss at chromosome 13q including important 
genes [RB1, CCNA1, CDC16, SETDB2, SOX1, MIR15A 
and MIR16-1]. We identified 42 somatic mutations in total 
that were validated by Sanger sequencing and mapped 
according to their tumor regions (Figure 6B). These 
mutations were categorized into 13 common mutations, 
2 shared mutations (present in 2 of the 3 regions), and 
27 private mutations (specifically present in a single 
region). Ongoing regional clonal evolution was indicated 
by the presence of unique mutations in each region: T1 
(7), T2 (12) and T3 (8) (Figure 6C). A phylogenetic tree 
of different tumor regions by clonal ordering shows 
branching tumor evolution (Figure 6D). Only 31% (13 
out of 42) of the total mutations were detected in all three 
regions of this single tumor highlighting the inadequacy of 
mutational interrogation at only a single tumor site.
DISCUSSION
LPS, although rare, is one of the most common soft 
tissue sarcomas with substantial morbidity and mortality. 
Previous studies have characterized genetic aberrations 
in LPS tumors identifying recurrent mutations of TP53, 
PIK3CA, RB1, and PTEN [7]. As a compliment to prior 
studies, we examined all histologic types of LPS by deep 
nucleotide sequencing and CNA analyses and focused on 
several aberrant genes.
CPM gene is present in one of the multiple-peaks 
of amplification on chromosome 12q. It belongs to 
the carboxypeptidases family and is a GPI anchored 
membrane-bound enzyme [13]. It specifically removes 
C-terminal basic residues (Arg or Lys) from peptides 
and proteins, and plays a role in the control of peptide 
hormone and growth factor activity at the cell surface 
[14]. Recent reports have suggested that CPM can be a 
potential cancer biomarker to discriminate WDLPS from 
lipomas [15] when coexpressed with EGFR with poor 
prognosis in adenocarcinoma of lung [16]. Assessment of 
copy number of both MDM2 and CPM has been proposed 
as a complementary tool for better classification of LPS 
tumors [17]. We showed that CPM could modulate EGFR 
signaling, and silencing of CPM decreased tyrosine 
kinase activity of EGFR. These observations suggest 
that lowering the enzymatic activity of CPM may have a 
therapeutic effect in patients with CPM amplification. We 
also noted that deletion at chromosome 13q14.2 occurred 
in approximately 16 out of 86 (19%) of LPS samples and 
cell lines. This deletion very frequently occurs in chronic 
lymphoid leukemia (CLL) [18], mantle cell lymphomas 
[19], multiple myeloma [20] and prostate cancers [21]. 
This region contains important tumor suppressors RB1, 
MIR15A and MIR16-1. Studies in CLL have shown 
BCL2 as the target of miR15/16 [22] and that ABT-199 
(Bcl2 inhibitor) is effective against these Bcl-2 elevated 
lymphoid malignancies [23]. Future studies need to 
measure levels of the anti-apoptotic proteins (Bcl-2) 
and determine if ABT-199 or similar drugs are effective 
in treatment of patients with LPS having a deletion of 
chromosome 13q14.2. 
In the field of cancer genomics, differentiation 
between somatic drivers of tumorigenesis versus 
passenger mutations is difficult. Mutation significance 
algorithm MUSIC [24] was used to identify genes 
(MXRA5, PLEC, NF1, FAT3 and MDC1) showing positive 
selection for mutation. This algorithm identifies genes that 
were mutated more often than expected by chance given 
the background mutation processes [24].
We identified recurrent mutations in previously 
unidentified genes in LPS, associated with cell adhesion, 
pathways involved in cytoskeleton organization, base 
excision repair, homologous recombination repair, 
nucleotide excision repair, as well as DNA replication 
process. Alteration of DNA damage repair genes can 
foster initiation of cancer by preventing senescence and 
apoptosis, and promoting cellular proliferation even in the 
presence of accumulation of DNA damage [25]. Another 
class of mutations includes semaphorins, slits, netrins and 
ephrins and these genes have important regulatory roles 
in axon guidance and in cancer cell growth, survival, 
invasion and angiogenesis (22). This pathway has been 
recently also found to be aberrated in pancreatic cancer 
[26]. Mutant genes of this class in LPS include ROBO1, 
SEMA3G and SEMA3A. Our study strongly suggest 
that dysregulation of axon guidance pathway may be 
associated with liposarcomagenesis which requires further 
investigation. 
NF1 gene encodes Neurofibromin which has 
significant homology to GTPase-activating proteins 
(GAPs) [27]. NF1 negatively regulates the RAS proto-
oncogene by catalyzing hydrolysis of RAS-GTP; the 
latter is important for cell proliferation, differentiation and 
migration [28]. Mutations of the NF1 gene in other types 
of cancer are associated with a highly aggressive often 
fatal outcome [29]. We found that NF1 gene was among 
the most recurrently aberrant gene in our LPS samples 
(20%); these included missense mutations, frameshift 
insertions and loss of heterozygosity. An earlier DNA 
sequencing study reported NF1 mutations only in PLPS 
type [7] but in our cohort mutations occurred irrespective 
of subtype. In further studies, we provided evidence for a 
potential tumor suppressor role of NF1 in vitro and in vivo.
Mutational activation of BRAF gene is already 
known to occur in melanoma, glioblastoma, thyroid, 
lung, colon and hematological malignancies [30]. We 
identified an oncogenic BRAF (V600E) mutation in 2 LPS 
cell lines [SW872 [30] and SA4] and noted unique BRAF 
mutations in 2 LPS fresh samples. BRAF mutant (V600E) 
melanoma and thyroid cancers are sensitive, but colon 
cancers are resistant to therapy with vemurafenib (FDA 
approved drug) [31]. LPS can now be added to the list of 
vemurafenib-sensitive tumors. LPS cells carrying BRAF 
V600E mutations were sensitive to inhibition by this 
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tyrosine kinase inhibitor while cells without the mutation 
were resistant to the drug. 
This study for the first time reported multi-region 
WES and SNP Chip analysis of a LPS patient’s tumor. 
Intra-tumor mutational and copy number heterogeneity 
was found including intra-tumor diversity at chromosome 
13q and 51% somatic mutations defined as unique to 
one of the three regions of the tumor. This heterogeneity 
suggests that determining therapy of LPS (personalized 
medicine) based on a single tumor biopsy may not provide 
a complete mutational landscape and multi-regional tumor 
biopsies may be needed to assess the genomic complexity 
and its clinical impact on the patient.
Many of the genetic alterations that we identified 
will alter important signaling pathways (e.g., MAPK, 
ErbB, p53, DNA repair and replication, cell cycle and 
axon guidance) (Supplementary Table S9). Genes which 
are therapeutic targets include MDM2, CDK4, NF1, 
BRCA1, EGFR, PI3K, AKT1, KIT, BRAF, ERBB2 and 
ERBB3. Also, several important unexplored targets were 
identified. This work represents a global genomic analysis 
of LPS cohort and provides insights into the development 
of novel therapeutic strategies based on molecular 
phenotype of the tumor. 
MATERIALS AND METHODS
Patients’ samples and cell lines
Primary human LPS tumor tissues and matched 
normal fat tissues of different histotypes were collected by 
collaborating with different hospitals [National University 
Hospital Tissue Repository (Singapore), University of 
California (Los Angeles, CA, USA), Tumor Repository 
at Yale University School of Medicine (New Haven, CT, 
USA), City of Hope Hospital (Duarte, CA, USA) and Oslo 
University Hospital Sarcoma Biobank (Oslo, Norway)]. 
Detailed clinical characteristics of all patients are provided 
in the Supplemental Table S1. Patients used for integrated 
genomic analyses: SNP array (86 tumors), Discovery 
cohort (12 tumor-normal pairs) for WES, and Prevalence 
cohort (14 tumor-normal pairs and 72 tumors) for TES. 
Thirteen human LPS cell lines were used in the 
present study: SW872 (undifferentiated LPS) was 
purchased from American Tissue Type Culture Collection 
(ATCC, Rockville, MD, USA); LP6 cells were provided 
by Dr Christopher DM Fletcher; SA-4 (liposarcoma) cell 
was a kind gift from Ola Myklebost; LiSa-2 (metastatic 
poorly differentiated liposarcoma) [32] was kindly 
provided by Dr. Moller; FU-DDLS-1 [33] and LPS141 
[34] (DDLPS) were gifts from Dr. Nishio and Dr. Fletcher, 
respectively. GOT-3 (recurrence of a myxoid variant of a 
WDLPS) [35] and MLS-402 (MLPS) [36] were generous 
gifts from Dr. Åman. T778 and T1000 (recurrent WDLPS) 
were kind gifts from Dr. Pedeutour. LPS1, LPS2, LPS3 
(DDLPS) cell lines were provided by Dr Hong Wu [37]. 
All these LPS cell lines were maintained in RPMI medium 
supplemented with fetal bovine serum in a humidified 
incubator at 370C with 5% CO2 [38].
Genomic DNA and RNA extraction
Genomic DNA (gDNA) was extracted from tumor 
tissues and cell lines using a QIAamp DNA Blood Mini 
Kit (Qiagen) according to manufacturer’s instructions. 
The Qubit dsDNA BR Assay Kit (Life technologies) was 
used to quantify the concentration of gDNA and also 0.7% 
agarose gel was run for quality of each gDNA sample. 
Total RNA was isolated using RNeasy Mini Kit (Qiagen) 
following kit’s instructions and quality and concentration 
of RNA was checked on Bioanalyzer 2100 (version A.02 
S1292, Agilent Technologies). 
SNP array analysis
SNP array analysis was performed using GeneChip 
human mapping SNP array (Affymetrix, Santa Clara, 
CA, USA). gDNA from 86 LPS tumor samples and 13 
cell lines were hybridized to Affymetrix 250K Nsp SNP 
array and CytoScan SNP array according to instructions 
provided by array manufacturers [39]. GeneChip Fluidics 
Station 400 and GeneChip scanner 3000 were used to 
produce raw data, which were processed and analyzed by 
copy number analyzer for Affymetrix GeneChip (CNAG 
3.0) using copy number analysis as described previously 
[40, 41]. Significantly recurrent copy number changes 
were identified using the GISTIC2.0 algorithm [42].
WES and TES sequencing
For WES, gDNA libraries were prepared using 
the SureSelect® Human All Exon 50M Kit V4 (Agilent 
Technologies) as described previously [43]. Captured 
DNA libraries were subjected to high through-put 
sequencing using Hiseq2000 Illumina platform with 75 
to 100 bp paired-end reads. TES included 248 genes in 
the customized target enrichment kit and targeted gene 
libraries were prepared with SureSelectXT2 Target 
Enrichment System for Illumina Multiplexed Sequencing 
(Agilent Technologies) according to manufacturer’s 
protocols. Captured libraries were subjected to massively 
parallel sequencing using HiSeq2000 platform (Illumina). 
Next-generation sequencing data processing and 
mutation calling
Somatic mutations and short insertions and deletions 
(Indels) from WES were detected using in-house analysis 
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pipeline as described previously [43-46]. Massively 
parallel sequencing reads were first aligned to hg19 
using Burrows-Wheeler Aligner (V 0.5.8) with default 
parameters. Low quality reads were filtered, including 
more than 5 mismatches to the reference sequences or 
whose mapping quality was less than 30 for summarizing 
base call data. The significance of each candidate single 
nucleotide variant (SNV) was evaluated by Fisher’s exact 
test by enumerating the number of the reference bases and 
the candidate SNV. Finally, a list of candidate somatic 
mutations was generated by excluding synonymous 
SNVs and other variants registered in dbSNP131, 1000 
genomes, or our in-house SNP database constructed 
from 180 samples [43, 44]. All the somatic mutations 
were validated by Sanger sequencing. To detect probable 
somatic mutations of non- paired LPS patient samples (no 
germ line control DNA) and LPS cell lines, besides all 
the above  mentioned criteria applied, we further removed 
copy number-neutral variants with allele frequency 
between 45% and 55% unless they were registered in the 
COSMIC data base.
Validation by sanger sequencing
All mutations and Indels found by next generation 
sequencing were validated with Sanger sequencing. 
PCR primers were designed for the putative variants 
using Primer3 and were used to amplify the source DNA 
from the tumors and germline control. Products were 
sequenced; and sequences were analyzed with Sequencing 
Analysis Software Version 5.2 (Applied Biosystems).
Analysis of significantly mutated genes and 
pathways
Validated list of SNVs and Indels across the cohort 
were used to identify significantly altered genes. We 
performed ‘Significantly Mutated Genes tests (SMG-test) 
from ‘Mutational Significance in Cancer’ (MuSiC) tool 
to identify such genes [24]. Each mutation is categorized 
into seven categories, AT transitions, AT transversions, 
CpG transitions, CpG transversions, CG transitions/
transversions and Indels. Final Background Mutation 
Rate (BMR) is estimated by dividing number of mutations 
found in each category and total number of available 
bases. A gene is identified as significantly mutated, if its 
mutation rate is significantly higher than the estimated 
BMR. The refseq annotated mutations (genes) were used 
for pathway analysis. Pathway analysis was done using 
PathScan algorithm integrated into MuSic pipeline [47].
Analysis of mutational signature
We used EMu, a probabilistic method which uses 
Expectation Maximization (EM) algorithm to identify 
Mutational Signatures. EMu also measures the tumor 
specific “opportunity” from CNAs to measure the 
“opportunity” for a given variant to occur in that region 
thus increasing the accuracy of inferred Signature. Along 
with the validated variants, we also used all high quality 
tier1 and tier2 variants from WES samples for Signature 
Analysis [48]. Before running Emu, mutation opportunity 
was calculated using CNAs in tumor. Briefly, read 
depths for every 100 base pair segments were estimated 
for tumor and matched normal samples, and depth ratio 
was calculated using VarScan2 copy number programme 
[49]. These segments were later delineated by Circular 
Binary Segmentation algorithm to detect potential copy 
number altered regions [50]. This segmented data was 
fed into Emu along with the mutations classified into 96 
trinucleotide channels based on the bases immediate to the 
5’ and 3’ of the mutated site. 
RT-PCR and quantitative real-time PCR analysis 
Total RNA was reverse transcribed to cDNA with 
RevertAid First Strand cDNA Synthesis Kit (Thermo 
Scientific). Quantitative gene expression levels were 
detected using KAPA-SYBR Green RT-PCR with the ABI 
PRISM 7500 Fast Sequence Detection System (Applied 
Biosystems). Expression levels of target genes were 
normal ized to GAPDH mRNA levels. Primer sequences 
are provided in Supplementary Table 10. 
Genomic quantitative PCR
gDNA of LPS patient samples was quantified and 
diluted at a concentration of 25 ng/ml. For reaction, 2X 
SYBR Green PCR master mix, forward and reverse 
primers specific for CPM were added and pipetted into 
respective wells of a PCR plate. gDNA (1 ul) was added 
in each well and run in ABI PRISM 7500 Fast Sequence 
Detection System (Applied Biosystems) at following 
conditions; 50°C for 2 min, denaturation at 95°C for 10 
min, followed by 40 cycles of denaturing at 95°C for 15 
s and combined annealing and extension at 60°C for 60 s. 
GAPDH specific primers were used as control. 
Immunohistochemistry
Tissue microarray slides were purchased from 
Super Bio Chips which were deparaffinized and hydrated 
in xylene and graded ethanol to distilled water. A 
blocking step to quench endogeneous peroxidase was 
performed in 0.3% H2O2 in 95% ethanol for 5 min and 
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antigen retrieval was done with a retrieval buffer (pH 6). 
Slides were blocked and incubated with CPM antibody 
for 30 min followed by washing. Secondary rabbit-
horse radish peroxidase labelled antibody was added, 
followed by washing and developed with DAB solution. 
Counterstaining was done with Mayers hematoxylin for 
5 min and slides were mounted and was scanned using 
the automated scanning system Aperio XT (Aperio 
Technologies).
Flow cytometry
For surface staining, cells were harvested, washed 
(single cell suspension) and resuspended (1-5 x 106 cells/
ml) in ice cold FACS Buffer (PBS, 2% FBS). Cells were 
blocked for 20 min and incubated with CPM antibody 
(1:100 dilution) for 30 min on ice. After washing with 
ice-cold FACS buffer, cells were subjected to secondary 
labeled antibody (1:500 dilution), incubated for 30 min in 
the dark on ice, washed three times and analyzed on flow 
cytometer.
For cell cycle analysis, cells were harvested, washed 
with ice-cold PBS and fixed using ice-cold 70% ethanol. 
Propidium iodide/RNase solution was added to cells 
on ice and analyzed by flow cytometer. Apoptosis was 
detected by flow cytometry using the Annexin V-FITC 
Apoptosis Detection kit (BD Pharmingen) according to 
the manufacturer’s instructions. 
Cell proliferation assay
Cells were seeded (5000 cells/well) in 96-well 
plates and MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) assay was performed at 
24 h, 48 h, 72 h and 96 h according to standard protocol. 
Cells were incubated with MTT (0.5 mg/ml) for 2-4 h in 
a 37˚C CO2 incubator. Formazan crystals were dissolved 
in 100 ul of MTT stop solution (SDS-HCl). Absorbance 
was measured at 570 nm using a Tecan Infinite 200 PRO 
spectrophotometer (Mannedorf, Switzerland). 
Colony formation assay
For anchorage-dependent colony assay, cells were 
seeded in 6-well plates (500 cells/well) and allowed to 
grow for 10-15 days to form colonies. Colonies were 
washed with PBS, fixed with methanol and stained with 
crystal violet. For anchorage-independent colony assays, 
cells were plated in 0.5% agarose on top of 1% agarose in 
24-well plates. Cells were allowed to grow for 2-3 weeks 
to form colonies; and colonies were counted under an 
inverted microscope.
Migration and invasion assay
Cells in serum-free medium were seeded in 
Transwell inserts (Corning) for migration assay and in 
Matrigel coated Transwell inserts for invasion assay in 24-
well plates. Cells were incubated with serum containing 
medium in the lower chamber. After 24 h, inserts were 
washed and non-migrating/non-invading cells were 
removed and migrated/invaded cells were fixed with 
methanol and stained with crystal violet. 
Immunoblot analysis
Cell lysates were prepared using Protein Extraction 
reagent (Thermo Scientific) containing protease inhibitor 
cocktail and subjected to SDS-PAGE. Proteins were 
transferred to polyvinyidene difluoride membranes which 
were further incubated with the indicated antibodies and 
detection was performed using Chemiluminescent HRP 
Substrate (Thermo Scientific). List of antibodies used are 
provided in Supplementary Table 11.
Xenograft assay
Male NOD SCID gamma mice (5-6 weeks old) 
were used for xenograft assay in compliance with 
ethical regulations of Institutional Animal Care and Use 
Committee of National University of Singapore. CPM 
shRNA3 knockdown LPS141 cells and non-target shRNA 
LPS141 cells (2 x 106 cells per mice) mixed with matrigel 
were injected subcutaneously in the right and left flank 
of the mice, respectively. After 4-6 weeks of injection, 
mice were eutha nized to weigh and analyze the dissected 
tumors.
RNA interference
Human CPM gene specific siRNA duplexes 
including control scramble siRNA duplexes were 
purchased from Integrated DNA Technologies 
(Coralville, USA). LPS141, FU-DDLS-1 and SW872 
cells were transfected with 100nM siRNA duplex using 
Nucleofector Kit (Lonza, Cologne, Germany) according 
to the manufacturer’s protocol. 2 ug of pmaxGFP vector 
was used to ensure transfection efficiency. The average 
transfection efficiency was approximately 60-70%. Cells 
were incubated for at least 48 h after nucleofection before 
performing experiments. Each experiment was performed 
at least in triplicate on three different occasions. 
To obtain stable knockdown of CPM and NF1 in 
LPS cells for in vitro and in vivo studies, human CPM 
and NF1 gene specific shRNAs and a non-targeting 
shRNA were cloned in a lentiviral vector. For stable 
knockdown, lentiviral particles were generated according 
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to the manufacturer’s protocol. Cells were infected with 
lentivirus particles at a MOI of 25 with 5 ug/ml polybrene 
(Sigma-Aldrich) for 24 h and stable cells were selected 
using 0.5-1 ug/ml puromycin for 2 weeks. 
Statistical analyses
Two-tailed Student’s t-test was used for the 
following assays: quantitative real-time PCR, cell 
proliferation assay, colony formation assay, cell cycle 
analysis, apoptosis assay, migration assay, invasion assay 
and xenograft growth assay. 
Study approval
Informed written consent was obtained from all the 
patients for the sample collection and their use in research 
and projects were approved by Ethical Review Boards.
ACKNOWLEDGMENTS
Dedicated to the memory of Wendy Landes who 
inspired this study. We thank Prof. Patrick Tan and Dr. Z. 
Zang for generously sharing related facilities. 
GRANT SUPPORT
This work was funded by the Singapore Ministry 
of Health’s National Medical Research Council (NMRC) 
under its Singapore Translational Research (STaR) 
Investigator Award to H. Phillip Koeffler, NMRC Centre 
Grant awarded to National University Cancer Institute of 
Singapore, the National Research Foundation Singapore 
and the Singapore Ministry of Education under its 
Research Centres of Excellence initiative and NCIS 
Centre Grant Seed Funding Program awarded by National 
University Cancer Institute, Singapore (NCIS). Myklebost 
and Meza-Zepeda were supported by a grant from the 
Liddy Shriver Sarcoma Initiative. H. Phillip Koeffler and 
Charles Forscher were supported by grant from Alan B. 
Slifka Foundation.
CONFLICTS OF INTEREST
The authors have declared that no conflict of interest 
exists.
REFERENCES
1. Mack TM. Sarcomas and other malignancies of soft tissue, 
retroperitoneum, peritoneum, pleura, heart, mediastinum, 
and spleen. Cancer. 1995; 75:211-244.
2. Dalal KM, Antonescu CR and Singer S. Diagnosis and 
management of lipomatous tumors. Journal of surgical 
oncology. 2008; 97:298-313.
3. Jo VY and Fletcher CD. WHO classification of soft 
tissue tumours: an update based on the 2013 (4th) edition. 
Pathology. 2014; 46:95-104.
4. Rosai J, Akerman M, Dal Cin P, DeWever I, Fletcher CD, 
Mandahl N, Mertens F, Mitelman F, Rydholm A, Sciot 
R, Tallini G, Van den Berghe H, Van de Ven W, Vanni 
R and Willen H. Combined morphologic and karyotypic 
study of 59 atypical lipomatous tumors. Evaluation of their 
relationship and differential diagnosis with other adipose 
tissue tumors (a report of the CHAMP Study Group). The 
American journal of surgical pathology. 1996; 20:1182-
1189.
5. Crozat A, Aman P, Mandahl N and Ron D. Fusion of 
CHOP to a novel RNA-binding protein in human myxoid 
liposarcoma. Nature. 1993; 363:640-644.
6. Pedeutour F, Forus A, Coindre JM, Berner JM, Nicolo 
G, Michiels JF, Terrier P, Ranchere-Vince D, Collin 
F, Myklebost O and Turc-Carel C. Structure of the 
supernumerary ring and giant rod chromosomes in adipose 
tissue tumors. Genes, chromosomes & cancer. 1999; 24:30-
41.
7. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-
Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, 
Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin 
Y, Beroukhim R, et al. Subtype-specific genomic alterations 
define new targets for soft-tissue sarcoma therapy. Nature 
genetics. 2010; 42:715-721.
8. Taylor BS, DeCarolis PL, Angeles CV, Brenet F, Schultz N, 
Antonescu CR, Scandura JM, Sander C, Viale AJ, Socci ND 
and Singer S. Frequent alterations and epigenetic silencing 
of differentiation pathway genes in structurally rearranged 
liposarcomas. Cancer discovery. 2011; 1:587-597.
9. Italiano A, Bianchini L, Keslair F, Bonnafous S, Cardot-
Leccia N, Coindre JM, Dumollard JM, Hofman P, Leroux 
A, Mainguene C, Peyrottes I, Ranchere-Vince D, Terrier 
P, Tran A, Gual P and Pedeutour F. HMGA2 is the partner 
of MDM2 in well-differentiated and dedifferentiated 
liposarcomas whereas CDK4 belongs to a distinct 
inconsistent amplicon. International journal of cancer 
Journal international du cancer. 2008; 122:2233-2241.
10. Lee DH, Amanat S, Goff C, Weiss LM, Said JW, Doan 
NB, Sato-Otsubo A, Ogawa S, Forscher C and Koeffler 
HP. Overexpression of miR-26a-2 in human liposarcoma 
is correlated with poor patient survival. Oncogenesis. 2013; 
2:e47.
11. McGwire GB and Skidgel RA. Extracellular conversion 
of epidermal growth factor (EGF) to des-Arg53-EGF by 
carboxypeptidase M. The Journal of biological chemistry. 
1995; 270:17154-17158.
12. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, 
Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, 
Borresen-Dale AL, Boyault S, Burkhardt B, Butler AP, 
Caldas C, Davies HR, Desmedt C, et al. Signatures of 
mutational processes in human cancer. Nature. 2013; 
Oncotarget42443www.impactjournals.com/oncotarget
500:415-421.
13. Shimamori Y, Kumagai Y, Watanabe Y and Fujimoto 
Y. Human placental carboxypeptidase M is anchored by 
a glycosyl-phosphatidylinositol moiety. Biochemistry 
international. 1990; 20:607-613.
14. Skidgel RA, McGwire GB and Li XY. Membrane 
anchoring and release of carboxypeptidase M: implications 
for extracellular hydrolysis of peptide hormones. 
Immunopharmacology. 1996; 32:48-52.
15. Erickson-Johnson MR, Seys AR, Roth CW, King AA, 
Hulshizer RL, Wang X, Asmann YW, Lloyd RV, Jacob 
EK and Oliveira AM. Carboxypeptidase M: a biomarker 
for the discrimination of well-differentiated liposarcoma 
from lipoma. Modern pathology : an official journal of the 
United States and Canadian Academy of Pathology, Inc. 
2009; 22:1541-1547.
16. Tsakiris I, Soos G, Nemes Z, Kiss SS, Andras C, Szanto 
J and Dezso B. The presence of carboxypeptidase-M in 
tumour cells signifies epidermal growth factor receptor 
expression in lung adenocarcinomas: the coexistence 
predicts a poor prognosis regardless of EGFR levels. 
Journal of cancer research and clinical oncology. 2008; 
134:439-451.
17. Zhang H, Erickson-Johnson M, Wang X, Oliveira 
JL, Nascimento AG, Sim FH, Wenger DE, Zamolyi 
RQ, Pannain VL and Oliveira AM. Molecular testing 
for lipomatous tumors: critical analysis and test 
recommendations based on the analysis of 405 extremity-
based tumors. The American journal of surgical pathology. 
2010; 34:1304-1311.
18. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, 
Bullinger L, Dohner K, Bentz M and Lichter P. Genomic 
aberrations and survival in chronic lymphocytic leukemia. 
The New England journal of medicine. 2000; 343:1910-
1916.
19. Stilgenbauer S, Nickolenko J, Wilhelm J, Wolf S, Weitz S, 
Dohner K, Boehm T, Dohner H and Lichter P. Expressed 
sequences as candidates for a novel tumor suppressor gene 
at band 13q14 in B-cell chronic lymphocytic leukemia and 
mantle cell lymphoma. Oncogene. 1998; 16:1891-1897.
20. Elnenaei MO, Hamoudi RA, Swansbury J, Gruszka-
Westwood AM, Brito-Babapulle V, Matutes E and 
Catovsky D. Delineation of the minimal region of loss 
at 13q14 in multiple myeloma. Genes, chromosomes & 
cancer. 2003; 36:99-106.
21. Dong JT, Boyd JC and Frierson HF, Jr. Loss of 
heterozygosity at 13q14 and 13q21 in high grade, high stage 
prostate cancer. Prostate. 2001; 49:166-171.
22. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, 
Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, 
Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini 
M, et al. miR-15 and miR-16 induce apoptosis by targeting 
BCL2. Proc Natl Acad Sci U S A. 2005; 102:13944-13949.
23. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron 
ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother 
WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar 
PJ, Lam LT, et al. ABT-199, a potent and selective BCL-
2 inhibitor, achieves antitumor activity while sparing 
platelets. Nat Med. 2013; 19:202-208.
24. Dees ND, Zhang Q, Kandoth C, Wendl MC, Schierding 
W, Koboldt DC, Mooney TB, Callaway MB, Dooling D, 
Mardis ER, Wilson RK and Ding L. MuSiC: identifying 
mutational significance in cancer genomes. Genome 
research. 2012; 22:1589-1598.
25. Hanahan D and Weinberg RA. Hallmarks of cancer: the 
next generation. Cell. 2011; 144:646-674.
26. Biankin AV, Waddell N, Kassahn KS, Gingras MC, 
Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch 
AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, 
Harliwong I, Idrisoglu S, et al. Pancreatic cancer genomes 
reveal aberrations in axon guidance pathway genes. Nature. 
2012; 491:399-405.
27. Buchberg AM, Cleveland LS, Jenkins NA and Copeland 
NG. Sequence homology shared by neurofibromatosis 
type-1 gene and IRA-1 and IRA-2 negative regulators of 
the RAS cyclic AMP pathway. Nature. 1990; 347:291-294.
28. Cichowski K and Jacks T. NF1 tumor suppressor gene 
function: narrowing the GAP. Cell. 2001; 104:593-604.
29. Ponti G, Martorana D, Pellacani G, Ruini C, Loschi P, 
Baccarani A, De Santis G, Pollio A, Neri TM, Mandel 
VD, Maiorana A, Maccio L, Maccaferri M and Tomasi A. 
NF1 truncating mutations associated to aggressive clinical 
phenotype with elephantiasis neuromatosa and solid 
malignancies. Anticancer research. 2014; 34:3021-3030.
30. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg 
S, Teague J, Woffendin H, Garnett MJ, Bottomley W, 
Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, et 
al. Mutations of the BRAF gene in human cancer. Nature. 
2002; 417:949-954.
31. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, 
Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, 
Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham 
D, Van Cutsem E, et al. Prognostic role of KRAS and 
BRAF in stage II and III resected colon cancer: results of 
the translational study on the PETACC-3, EORTC 40993, 
SAKK 60-00 trial. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology. 
2010; 28:466-474.
32. Wabitsch M, Bruderlein S, Melzner I, Braun M, 
Mechtersheimer G and Moller P. LiSa-2, a novel human 
liposarcoma cell line with a high capacity for terminal 
adipose differentiation. International journal of cancer 
Journal international du cancer. 2000; 88:889-894.
33. Nishio J, Iwasaki H, Ishiguro M, Ohjimi Y, Fujita C, 
Ikegami H, Ariyoshi A, Naito M, Kaneko Y and Kikuchi 
M. Establishment of a novel human dedifferentiated 
liposarcoma cell line, FU-DDLS-1: conventional and 
molecular cytogenetic characterization. International 
journal of oncology. 2003; 22:535-542.
Oncotarget42444www.impactjournals.com/oncotarget
34. Snyder EL, Sandstrom DJ, Law K, Fiore C, Sicinska E, 
Brito J, Bailey D, Fletcher JA, Loda M, Rodig SJ, Dal Cin 
P and Fletcher CD. c-Jun amplification and overexpression 
are oncogenic in liposarcoma but not always sufficient 
to inhibit the adipocytic differentiation programme. The 
Journal of pathology. 2009; 218:292-300.
35. Persson F, Olofsson A, Sjogren H, Chebbo N, Nilsson 
B, Stenman G and Aman P. Characterization of the 12q 
amplicons by high-resolution, oligonucleotide array CGH 
and expression analyses of a novel liposarcoma cell line. 
Cancer letters. 2008; 260:37-47.
36. Aman P, Ron D, Mandahl N, Fioretos T, Heim S, Arheden 
K, Willen H, Rydholm A and Mitelman F. Rearrangement 
of the transcription factor gene CHOP in myxoid 
liposarcomas with t(12;16)(q13;p11). Genes, chromosomes 
& cancer. 1992; 5:278-285.
37. Braas D, Ahler E, Tam B, Nathanson D, Riedinger M, Benz 
MR, Smith KB, Eilber FC, Witte ON, Tap WD, Wu H and 
Christofk HR. Metabolomics strategy reveals subpopulation 
of liposarcomas sensitive to gemcitabine treatment. Cancer 
discovery. 2012; 2:1109-1117.
38. Stratford EW, Castro R, Daffinrud J, Skarn M, Lauvrak 
S, Munthe E and Myklebost O. Characterization of 
liposarcoma cell lines for preclinical and biological studies. 
Sarcoma. 2012; 2012:148614.
39. Maciejewski JP, Tiu RV and O’Keefe C. Application of 
array-based whole genome scanning technologies as a 
cytogenetic tool in haematological malignancies. British 
journal of haematology. 2009; 146:479-488.
40. Bengtsson H, Wirapati P and Speed TP. A single-array 
preprocessing method for estimating full-resolution raw 
copy numbers from all Affymetrix genotyping arrays 
including GenomeWideSNP 5 & 6. Bioinformatics. 2009; 
25:2149-2156.
41. Hupe P, Stransky N, Thiery JP, Radvanyi F and Barillot E. 
Analysis of array CGH data: from signal ratio to gain and 
loss of DNA regions. Bioinformatics. 2004; 20:3413-3422.
42. Mermel CH, Schumacher SE, Hill B, Meyerson ML, 
Beroukhim R and Getz G. GISTIC2.0 facilitates sensitive 
and confident localization of the targets of focal somatic 
copy-number alteration in human cancers. Genome biology. 
2011; 12:R41.
43. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, 
Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki 
M, Chalkidis G, Suzuki Y, Shiosaka M, Kawahata R, 
Yamaguchi T, Otsu M, et al. Frequent pathway mutations 
of splicing machinery in myelodysplasia. Nature. 2011; 
478:64-69.
44. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, 
Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki 
H, Nagata Y, Yoshida K, Kon A, Suzuki Y, Chiba K, 
Tanaka H, et al. Integrated molecular analysis of clear-cell 
renal cell carcinoma. Nature genetics. 2013; 45:860-867.
45. Sakaguchi H, Okuno Y, Muramatsu H, Yoshida K, 
Shiraishi Y, Takahashi M, Kon A, Sanada M, Chiba 
K, Tanaka H, Makishima H, Wang X, Xu Y, Doisaki S, 
Hama A, Nakanishi K, et al. Exome sequencing identifies 
secondary mutations of SETBP1 and JAK3 in juvenile 
myelomonocytic leukemia. Nature genetics. 2013; 45:937-
941.
46. Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, 
Sato-Otsubo A, Sanada M, Park MJ, Terui K, Suzuki H, 
Kon A, Nagata Y, Sato Y, Wang R, Shiba N, Chiba K, et 
al. The landscape of somatic mutations in Down syndrome-
related myeloid disorders. Nature genetics. 2013; 45:1293-
1299.
47. Wendl MC, Wallis JW, Lin L, Kandoth C, Mardis ER, 
Wilson RK and Ding L. PathScan: a tool for discerning 
mutational significance in groups of putative cancer genes. 
Bioinformatics. 2011; 27:1595-1602.
48. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan 
MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, 
McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott 
RM, Vickery TL, Reed JS, et al. Recurring mutations found 
by sequencing an acute myeloid leukemia genome. The 
New England journal of medicine. 2009; 361:1058-1066.
49. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, 
Lin L, Miller CA, Mardis ER, Ding L and Wilson RK. 
VarScan 2: somatic mutation and copy number alteration 
discovery in cancer by exome sequencing. Genome 
research. 2012; 22:568-576.
50. Olshen AB, Venkatraman ES, Lucito R and Wigler M. 
Circular binary segmentation for the analysis of array-based 
DNA copy number data. Biostatistics. 2004; 5:557-572.
